As the U.S. stock market navigates a mixed landscape, with major indices showing varied movements and recent selloffs impacting investor sentiment, opportunities may arise for those looking to identify stocks that are trading below their estimated value. In such an environment, finding undervalued stocks involves assessing companies with strong fundamentals and potential resilience amid broader market fluctuations.
Name | Current Price | Fair Value (Est) | Discount (Est) |
German American Bancorp (NasdaqGS:GABC) | $39.82 | $74.94 | 46.9% |
Northwest Bancshares (NasdaqGS:NWBI) | $12.65 | $24.45 | 48.3% |
Old National Bancorp (NasdaqGS:ONB) | $23.97 | $45.88 | 47.8% |
Sandy Spring Bancorp (NasdaqGS:SASR) | $32.99 | $64.53 | 48.9% |
Solaris Energy Infrastructure (NYSE:SEI) | $29.34 | $57.34 | 48.8% |
Incyte (NasdaqGS:INCY) | $71.38 | $135.08 | 47.2% |
Limbach Holdings (NasdaqCM:LMB) | $83.35 | $160.26 | 48% |
Array Technologies (NasdaqGM:ARRY) | $6.90 | $13.50 | 48.9% |
Open Lending (NasdaqGM:LPRO) | $5.44 | $10.49 | 48.2% |
Haemonetics (NYSE:HAE) | $63.45 | $121.99 | 48% |
We'll examine a selection from our screener results.
Overview: Bruker Corporation, along with its subsidiaries, is involved in the development, manufacturing, and distribution of scientific instruments and analytical and diagnostic solutions globally, with a market cap of approximately $7.81 billion.
Operations: The company's revenue segments include Bruker Nano at $1.10 billion, Bruker CALID at $1.09 billion, Bruker Biospin at $905.70 million, and Bruker Energy & Supercon Technologies (BEST) at $283 million.
Estimated Discount To Fair Value: 17.3%
Bruker is trading at US$52.92, below its estimated fair value of US$63.96, suggesting it may be undervalued based on cash flows. Despite a decline in profit margins and net income due to large one-off items, earnings are expected to grow significantly over the next three years, outpacing the broader U.S. market. However, Bruker's revenue growth forecast (5.2% annually) lags behind market averages and debt coverage by operating cash flow remains a concern.
Overview: Fluence Energy, Inc. operates through its subsidiaries to offer energy storage and optimization software for renewable and storage applications across various regions including the Americas, Asia Pacific, Europe, the Middle East, and Africa, with a market cap of approximately $1.34 billion.
Operations: Fluence Energy's revenue primarily comes from its Batteries / Battery Systems segment, which generated $2.52 billion.
Estimated Discount To Fair Value: 43%
Fluence Energy is trading at US$7.36, significantly below its estimated fair value of US$12.90, indicating potential undervaluation based on cash flows. Despite experiencing a volatile share price and a recent revenue decline to US$186.79 million, earnings are forecasted to grow 42.23% annually as the company moves towards profitability in three years. Recent agreements for large-scale battery storage projects and innovative product launches like Smartstack™ bolster its growth prospects amidst industry challenges.
Overview: Solaris Energy Infrastructure, Inc. designs and manufactures specialized equipment for oil and natural gas operators in the United States, with a market cap of $2.01 billion.
Operations: Solaris Energy Infrastructure generates revenue primarily through its Solaris Logistics Solutions segment, which accounts for $275.40 million.
Estimated Discount To Fair Value: 48.8%
Solaris Energy Infrastructure, trading at US$29.34, is significantly undervalued relative to its estimated fair value of US$57.34 based on cash flow analysis. Despite high debt levels and a volatile share price, the company reported increased quarterly revenue of US$96.3 million and net income growth to US$6.25 million year-over-year. Earnings are forecasted to grow substantially at 83% annually, outpacing market averages, although profit margins have declined from 7.6% to 4.6%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com